Company GLG Pharma S.A.

GLG Pharma SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the research and development of therapies based on small molecules and formulations, which inhibit dysfunctional Signal Transducer and Activators of Transcription (STAT3) signaling. STAT3 is a signaling protein, which optimizes the human cell growth. The Company develops projects related to cancer and kidney disease treatment, as well as other drug applications. Its pipeline includes STAT3 inhibitors that mainly aim at treatment of chronic lymphatic leukemia (CLL), polycystic kidney disease (PKD) and triple negative breast cancer (TNBC). The Company performs clinical trials in laboratories located in Poland and the United States.